Peter Hau - Researcher Profile | RDL Research Database

Publications

2 shown

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp , Monika E. Hegi , Warren Mason +21 more

In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NC...

2009 The Lancet Oncology 7605 citations

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Monika E. Hegi , Annie‐Claire Diserens , Thierry Gorlia +13 more

Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.

2005 New England Journal of Medicine 7001 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 14,606
Institution: University of Regensburg

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-3894-5053

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.